Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Gilead

Gilead Sciences Pops On A New $4 Billion Opportunity In HIV Prevention

Gilead stock popped Thursday after the biotech giant said its twice-yearly shot prevented 99.9% of HIV infections in a study.

Investors Business Daily

Is Gilead Sciences Stock Underperforming the Dow?

Is Gilead Sciences Stock Underperforming the Dow?

Despite Gilead Sciences' underperformance relative to the Dow Jones Industrial Average over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Gilead Stock Dips As 'Non-Core' Products Drive Its Second-Quarter Beat

Gilead Stock Dips As 'Non-Core' Products Drive Its Second-Quarter Beat

Gilead stock dipped Friday after beating second-quarter expectations on the back of stronger-than-expected sales of non-core products.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Do Wall Street Analysts Like Gilead Sciences Stock?

Gilead Sciences has underperformed the broader market over the past year, yet Wall Street analysts remain moderately bullish about the stock’s prospects.

Experts say a twice-yearly injection that offers 100% protection against HIV is 'stunning'

A study shows that a twice-yearly shot was 100% effective in preventing new HIV infections in women in Africa

The Independent UK

UN Urges Gilead To 'Make History' With Game-changing HIV Drug

Gilead could bring the AIDS pandemic towards an end if the US pharmaceutical giant opens up access to its game-changing new HIV drug, the head of UNAIDS told AFP. Winnie Byanyima urged Gilead to "make history" by allowing generic manufacturing of Lenacapavir, a twice-yearly injectable antiretroviral medication used to treat…

International Business Times

Gilead Sciences' Q2 2024 Earnings: What to Expect

Gilead Sciences is expected to release its fiscal second-quarter earnings next month, and analysts project a double-digit profit increase.

inkl

Read news from The Economist, FT, and more,
with one subscription

Why A Broken Wing Butterfly Might Make Money In Gilead Sciences Stock

Why A Broken Wing Butterfly Might Make Money In Gilead Sciences Stock

Support for Gilead shares sits near 57.

Investors Business Daily

Gilead Flashes A Bullish Sign After HIV Drug Proves 100% Effective

Gilead Flashes A Bullish Sign After HIV Drug Proves 100% Effective

Gilead stock surged Thursday after its twice-annual shot proved 100% effective in preventing HIV infections in cisgender women.

Investors Business Daily

Is Gilead Sciences Stock Underperforming the Nasdaq?

Is Gilead Sciences Stock Underperforming the Nasdaq?

Gilead Sciences has recently underperformed the broader Nasdaq Composite, but analysts are reasonably bullish about the stock’s outlook.

Gilead Has A Narrative-Changing Revelation For Its Weight-Loss Contender

Gilead Has A Narrative-Changing Revelation For Its Weight-Loss Contender

Gilead stock reversed lower Monday after confirming it's testing a popular weight-loss mechanism as a treatment for a liver disease.

Investors Business Daily

Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar

Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar

Gilead stock jumped Friday after surprising Wall Street with preclinical test results for an under-the-radar weight-loss drug.

Investors Business Daily

3 Dividend Growth Stocks to Buy and Hold

3 Dividend Growth Stocks to Buy and Hold

These three dividend-paying growth stocks are worth a look at current levels as the odds rise for Fed rate cuts.

Pharma Firm Urged To Share New 'Game-changer' HIV Drug

Pharma Firm Urged To Share New 'Game-changer' HIV Drug

More than 300 politicians, health experts and celebrities on Thursday called for US pharmaceutical giant Gilead to allow cheap, generic versions of a promising new HIV drug to be produced so it can reach people in developing countries most affected by the deadly disease.

International Business Times

Get all your
news in one place.

100’s of premium titles.
One news app.

Gilead Sciences Stock Outlook: Is Wall Street Bullish or Bearish?

Gilead Sciences has underperformed the broader market YTD, but Wall Street analysts are still cautiously optimistic about the stock’s prospects.

Investors Business Daily

Gilead Gives Up Big Gains As Covid Drug Drives Its Beat — Again

Gilead stock pared its gains Friday after beating first-quarter sales forecasts on the back of its Covid treatment, Veklury.

Stocks Plunge Before the Open as Meta’s Revenue Forecast Disappoints, U.S. GDP Data and Earnings in Focus

June S&P 500 E-Mini futures (ESM24) are down -0.53%, and June Nasdaq 100 E-Mini futures (NQM24) are down -0.87% this morning as a disappointing revenue outlook for the current quarter from Meta weighed on sentiment, while market participants braced for a new round of U.S. economic data and quarterly reports…

Lawsuits Against Gilead Sciences Could Stifle Medical Innovation

Lawsuit against Gilead Sciences raises concerns about innovation impact in drug development and potential implications on future product development.

Get all your
news in one place.

100’s of premium titles.
One news app.

Is Gilead Sciences Stock a Buy Near 52-Week Lows for Its 4% Yield?

Gilead Sciences stock has trailed the broader markets by a significant margin over the last eight years. Is this high-yield dividend stock a good buy right now?

Investors Business Daily

CymaBay Rockets After Gilead Snaps Up The Liver-Focused Biotech For $4.3 Billion

CymaBay stock skyrocketed Monday after Gilead Sciences announced it will buy it for $4.3 billion. CBAY stock surged almost 25%.

Investors Business Daily

Gilead Reports 'Mildly Disappointing' Quarterly Results With An Unexpected High Point

Gilead had a "mildly disappointing" fourth quarter that featured two high-profile misses from HIV drugs. GILD stock hit a four-month low.

Gilead (GILD) Quarterly Earnings: Buy or Sell Signal?

Biotech major Gilead Sciences (GILD) will release its fourth-quarter results on February 6. The company is expected to report growth in earnings over the prior-year quarter, but its revenue is expected to decline. Given the expected decline in its revenue, how should investors play this stock? Read on to learn…

Investors Business Daily

How To Invest: The Slow Saucer Base Can Produce Quick Returns

Though it can technically be as short as seven weeks, most saucer bases develop over months or even years.

Investors Business Daily

Is Gilead's 10% Crash — Resulting In A Failed Breakout — An Overreaction?

Gilead said Monday its drug, Trodelvy, failed to pass muster in a study of patients with lung cancer, and GILD stock toppled.

Investors Business Daily

Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead

Arcellx and Gilead's Kite division deepened their collaboration in cancer treatments on Wednesday. ACLX stock rocketed into a breakout.

People

Dipanjan BanchurSince

Winnie Byanyima

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Intel Corporation

Investor Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Developing Countries

Places

276,768 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play